Correlation Engine 2.0
Clear Search sequence regions


  • adult (1)
  • asthma (3)
  • bone marrow (3)
  • cytokines (3)
  • eosinophil (2)
  • female (1)
  • human (4)
  • human- cells (1)
  • IL 13 (1)
  • IL 5 (1)
  • immunoglobulins e (3)
  • interleukin 4 (1)
  • levels immunoglobulins (1)
  • lung (1)
  • mesenchymal stem cells (10)
  • mice (2)
  • mice balb c (1)
  • nasal (2)
  • nasal cavity (1)
  • nose (1)
  • ovalbumin (1)
  • phase (3)
  • rhinitis (3)
  • serum (1)
  • stem (1)
  • stem cells (2)
  • Th2 (3)
  • th2 cells (1)
  • Sizes of these terms reflect their relevance to your search.

    We previously found that mesenchymal stem cells (MSCs) derived from human-induced pluripotent stem cells (iPSCs) exerted immunomodulatory effects on Th2-mediated allergic rhinitis in vitro. However, their contribution to the asthma and allergic rhinitis in animal models remains unclear. In this study, we developed a mouse model of ovalbumin (OVA)-induced allergic inflammation in both the upper and lower airways and evaluated the effects of the systemic administration of human iPSC-MSCs and bone marrow-derived MSCs (BM-MSCs) on allergic inflammation. Our results showed that treatments with both the iPSC-MSCs and BM-MSCs before the challenge phase protected the animals from the majority of allergy-specific pathological changes. This protection included an inhibition of inflammatory cell infiltration and mucus production in the lung, a reduction in eosinophil infiltration in the nose, and a decrease in inflammatory cell infiltration in both the bronchoalveolar and nasal lavage fluids. In addition, treatment with iPSC-MSCs or BM-MSCs before the challenge phase resulted in reduced serum levels of Th2 immunoglobulins (e.g., IgE) and decreased levels of Th2 cytokines including interleukin (IL)-4, IL-5, or IL-13 in the bronchoalveolar and/or nasal lavage fluids. Similar therapeutic effects were observed when the animals were pretreated with human iPSC-MSCs before the sensitization phase. These data suggest that iPSC-MSCs may be used as an alternative strategy to adult MSCs in the treatment of asthma and allergic rhinitis. Copyright © 2012 AlphaMed Press.

    Citation

    Yue-Qi Sun, Meng-Xia Deng, Jia He, Qing-Xiang Zeng, Weiping Wen, David S H Wong, Hung-Fat Tse, Geng Xu, Qizhou Lian, Jianbo Shi, Qing-Ling Fu. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem cells (Dayton, Ohio). 2012 Dec;30(12):2692-9

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 22987325

    View Full Text